1. Benign prostatic hyperplasia (BPH) causing bladder outlet obstruction
   Most likely if there is weak stream, hesitancy, straining, intermittency, nocturia, or dribbling.
2. Diabetic bladder dysfunction (diabetic cystopathy)
   Poorly controlled diabetes can damage bladder nerves and muscle, causing reduced bladder sensation, weak contraction, increased post-void residual urine, hesitancy, and incomplete emptying. This can coexist with BPH. Campbell-Walsh-Wein Urology, p. 3491. Harrison also describes diabetic cystopathy as impaired sensation and failure to empty, followed by increased residual urine and recurrent UTI risk.
3. Conditions that must be excluded before labeling this as BPH alone:
   • Urinary tract infection, even if painless
   • Urethral stricture
   • Prostatitis
   • Bladder stone
   • Chronic urinary retention with hydronephrosis or kidney impairment
   • Prostate cancer, especially if abnormal digital rectal examination or PSA, though cancer is not the usual cause of these symptoms
   • Medication-related retention, constipation, neurologic disease

Urgency

• Complete inability to pass urine
• Painful/distended lower abdomen
• Fever, chills, vomiting, or flank pain
• Visible blood in urine
• New leg weakness, saddle numbness, or loss of bowel control
• Marked drowsiness, dehydration, or very high blood glucose symptoms

Recommended evaluation

Likely initial treatment, after assessment

1. If BPH-related obstruction is likely and PVR is not dangerously high

• Tamsulosin 0.4 mg once daily, usually after the same meal each day, or
• Alfuzosin, depending on availability and clinician judgment.

2. If prostate enlargement is confirmed

• Finasteride 5 mg once daily, or
• Dutasteride 0.5 mg once daily.

3. If diabetic cystopathy or weak bladder contraction is significant

• Strict improvement of glycemic control
• Timed voiding, for example every 3 to 4 hours while awake
• Double voiding: urinate, wait briefly, then try again
• Treat constipation
• Intermittent self-catheterization if residual urine is persistently high or renal/UTI complications develop
• Urodynamic testing to distinguish obstruction from poor detrusor contractility

4. If urinary retention is substantial

• Prompt bladder drainage with a urethral catheter or suprapubic catheter
• Urgent urology review
• Assessment for obstruction and renal complications
• Later definitive BPH treatment or catheterization plan, depending on the cause

Diabetes, blood pressure, and cardiac-risk management

• Check HbA1c now and review home glucose values, diet, adherence, renal function, weight, and complications.
• Metformin 500 mg alone may be inadequate, but it should not be increased or combined with other drugs without checking eGFR, HbA1c, and contraindications.
• Because he has hypertension and prior LVH, his clinician should consider diabetes agents with cardiovascular and kidney benefit when indicated, such as an SGLT2 inhibitor or a GLP-1 receptor agonist. Selection depends on HbA1c, kidney function, weight, heart-failure status, affordability, and adverse-effect risks.
• Continue telmisartan only as prescribed, but reassess BP, potassium, and creatinine. The history calls it both stage 1 and stage 2 hypertension, so current average BP readings are needed.
• Check lipid profile and assess whether he needs statin therapy, which is commonly indicated in diabetes at age 50 depending on overall cardiovascular risk.

Practical plan for this patient

1. Book a urology or primary-care appointment urgently, within 1 week.
2. Obtain urinalysis, PVR bladder scan, creatinine/eGFR, HbA1c, urine albumin-creatinine ratio, and prostate assessment.
3. Do not self-start tamsulosin, finasteride, antibiotics, or herbal “prostate” medicines.
4. Avoid excess evening fluids, alcohol, and caffeine. Do not restrict fluids excessively if glucose is high or dehydrated.
5. Treat constipation and avoid over-the-counter cold/allergy products containing decongestants or sedating antihistamines, which can precipitate urinary retention.
6. Review response 4 to 12 weeks after treatment is started, sooner if symptoms worsen.
7. Escalate to procedural BPH treatment if medication fails or if there are recurrent retention, recurrent UTI, bladder stones, gross hematuria due to BPH, kidney impairment/hydronephrosis, or patient preference.

• AUA = American Urological Association. It is a professional body for urology specialists that publishes clinical guidelines.
  • In some forms, AUA Symptom Score refers to a questionnaire, also called the IPSS (International Prostate Symptom Score), used to measure urinary symptoms such as weak stream, hesitancy, frequency, nocturia, and incomplete emptying.
• PVR = post-void residual urine. It means the amount of urine left in the bladder immediately after the patient urinates.

• Below 50 mL is often considered normal.
• More than 200 mL, especially with symptoms, is concerning.
• A high PVR can result from prostate obstruction (BPH) or from a weak bladder due to diabetic autonomic neuropathy. It needs clinical assessment because persistent retention can lead to UTIs and kidney problems.

How dutasteride may help the urinary symptoms

• Improve weak stream and incomplete emptying
• Reduce the chance of acute urinary retention
• Reduce the likelihood of needing BPH surgery

Important limitation in this particular patient

• PVR bladder scan after passing urine
• Urine test
• Kidney function tests: creatinine/eGFR
• Prostate examination and usually prostate assessment/PSA discussion
• HbA1c and glucose-management review

Is an alpha-blocker needed?

Dutasteride precautions

• Obtain or discuss a baseline PSA and digital rectal exam where appropriate.
• Dutasteride decreases PSA by about 50% within 3 to 6 months. Future PSA results must be interpreted with this in mind. A subsequent confirmed PSA rise while taking it needs medical review. See the official dutasteride prescribing information.

• Reduced libido
• Erectile dysfunction
• Reduced semen volume or ejaculatory changes
• Breast tenderness or enlargement
• Mood changes in some patients

Bottom line

• Telmisartan 40 mg
• Metoprolol 47.5 mg

Practical clinical approach

1. Seated and standing BP and pulse
   Measure after 5 minutes lying/sitting, then again after standing 1 and 3 minutes. Ask specifically about dizziness, near-fainting, falls, fatigue, or blurred vision.
2. Why metoprolol is required
   His history of LVH and hypertension matters. Confirm whether the 47.5 mg formulation is metoprolol succinate and why it was prescribed. It should not be stopped suddenly, because abrupt beta-blocker withdrawal can be harmful.
3. PVR bladder scan, urinalysis, creatinine/eGFR
   These determine whether there is significant urinary retention and whether tamsulosin is appropriate versus urgent catheterization/urology assessment.
4. Heart rate and ECG when indicated
   Metoprolol can limit the heart-rate response to low BP, so he may not develop obvious palpitations even if BP drops.

If the clinician decides tamsulosin is appropriate

• Use the standard 0.4 mg once daily, taken 30 minutes after the same meal each day.
• Do not increase to 0.8 mg in a patient with low-normal BP without specialist review.
• Monitor home BP and symptoms closely during the first week.
• Rise slowly from bed or a chair, maintain reasonable hydration, and avoid driving or climbing if dizzy.
• Avoid alcohol excess.
• Avoid using sildenafil, tadalafil, or similar erectile-dysfunction drugs at the same time unless the clinician specifically approves it, because the combination can cause symptomatic hypotension.

When tamsulosin should be deferred or stopped and urgently reviewed

• Dizziness, fainting, or falls
• Standing systolic BP below about 90 mmHg or symptomatic low BP
• Very slow pulse or new weakness
• Complete inability to pass urine
• Fever, lower-abdominal pain/distension, flank pain, or blood in urine